@sands_jacob with Dellphi305 — tarlatamab w durvalumab vs durvalumab for small cell lung cancer — almost doubling of overall survival w manageable CRS & outpatient treatment. Standing ovation for small cell! @nejm concurrent pub today.
@oncoalert @myESMO #ESMO26
32 浏览 · 2 赞 · 2 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) · x.com